Arthneeti
FB

Fermenta Biotech Ltd

Q4 FY24Pharmaceuticals & Biotechnology

Fermenta Biotech Ltd Q4 FY24 Results & Presentation Highlights: Revenue, Margins & Order Book

Q4 FY24 investor presentation: what the company reported on revenue, margins and projects.

Price₹478
Market cap₹1.4K Cr
P/E25.5
Updated24 Sept 2026
Read3 min read

Based on Fermenta Biotech Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11) - Q4-FY24 Standalone Operational Revenue: INR 897 Mn, down 10.8% YoY (Page 9) - Volume of Vitamin D3 for Human Nutriti Quarterly EBITDA (Consolidated, Q4-FY24): INR 54 Mn, down 72.0% YoY (Q4-FY23: INR 193 Mn) - Quarterly Operating Margin (Consolidated, Q4-FY24): 5.55%, down from 18.35% YoY - Quarterly Prof

From Fermenta Biotech Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11)
  • Q4-FY24 Standalone Operational Revenue: INR 897 Mn, down 10.8% YoY (Page 9)
  • Volume of Vitamin D3 for Human Nutrition in Q4-FY24: 111% higher compared to Q3-FY24 but 18% lower in FY24 vs FY23 (Page 7)
  • Average prices of Vitamin D3 for Human Nutrition in FY24: 5% higher compared to FY23 (Page 7)
  • Animal Feed volumes and prices remain subdued (Page 7)

2 more points management made on revenue & sales performance

Profitability & Margins

See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The presentation does not explicitly mention specific details on capex, capacity expansion, or new plant/projects including amounts, status, or timelines. It focuses mainly on financial performance, operational highlights, and business overview without detailing ongoing or planned capital expenditures or capacity additions.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation for Fermenta Biotech Limited does not explicitly mention any details regarding order book, order inflow, or pending orders. The presentation primarily focuses on: - Financial performance (operational revenue, EBITDA, PAT) - Segment-wise revenue mix - Operational highlights including volume and price trends for Vitamin D3 - Balance sheet and income statement data

2 more points management made on order book & pipeline

Fermenta Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹122 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Fermenta Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Bharat Parenterals Ltd (Q4 FY24)

    For Q4 FY 2024, consolidated revenue from operations was INR 67.82 crore, up 13.4% YoY (Q4 FY 2023: INR 59.82 crore). Key investor presentation takeaways from B

  • Themis Medicare Ltd (Q4 FY24)

    97.82 Cr, up 22.11% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY24 investor presentation — and how it ranks against sector

  • Amrutanjan Health Care Ltd (Q4 FY24)

    OTC: ₹108.37 Cr, up 27.57% YoY (Q4 FY23: ₹84.95 Cr) . Key investor presentation takeaways from Amrutanjan Health Care Ltd's Q4 FY24 investor presentation — and

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Fermenta Biotech Ltd Q4 FY24 results?

Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11) - Q4-FY24 Standalone Operational Revenue: INR 897 Mn, down 10.8% YoY (Page 9) - Volume of Vitamin D3 for Human Nutriti Quarterly EBITDA (Consolidated, Q4-FY24): INR 54 Mn, down 72.0% YoY (Q4-FY23: INR 193 Mn) - Quarterly Operating Margin (Consolidated, Q4-FY24): 5.55%, down from 18.35% YoY - Quarterly Prof

What is Fermenta Biotech Ltd share price analysis?

Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.

Is Fermenta Biotech Ltd planning capital expenditure?

The presentation does not explicitly mention specific details on capex, capacity expansion, or new plant/projects including amounts, status, or timelines.

Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.